📰 Acticor Biotech News
Page 4 - Acticor Biotech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Acticor Biotech. Real-time updates on events, politics, business and more.
December 23, 2022
Regulatory News: Acticor Biotech, (ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular
December 1, 2022
Regulatory News: Acticor Biotech (Euronext Growth Paris ISIN: FR0014005OJ5 ALACT) (Paris:ALACT), a clinical-stage biopharmaceutical company, a spin-off of INSERM, developing an innovative drug for
November 24, 2022
A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the UK: the Queen Elizabeth ...
November 23, 2022
Acticor Biotech's glenzocimab, a potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K.
November 23, 2022
The first clinical trial for new heart attack drug glenzocimab, will evaluate its ability to reduce heart damage following a heart attack.
November 22, 2022
Regulatory News: Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug
November 22, 2022
22.11.2022 - Regulatory News: Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time. A potential new drug to improve the ... Seite 1
October 27, 2022
Significant clinical progress in the treatment of stroke with glenzocimab: Positive results from the ACTIMIS phase 1b/2a study Patent granted to protect glenzocimab in thrombotic
September 26, 2022
Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke
September 26, 2022
The first U.S. patient was enrolled in a study evaluating glenzocimab in those with acute ischemic stroke.